Third ultrasound diagnosis product for osteoporosis approved
This article was originally published in Clinica
Lunar has been given the go-ahead from the FDA to sell its ultrasound device for measuring bone density at the heel and predicting the risk of osteoporosis-related fractures. The company, of Madison, Wisconsin, has been selling the Achilles+ device outside the US since 1992.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.